Screening for Pancreatic Cancer in a High-risk Cohort: an Eight-year Experience

Overview

Journal J Gastrointest Surg

Specialty Gastroenterology

Date 2011 Dec 1

PMID 22127781

Citations 75

Authors

Wigdan Al-Sukhni

Ayelet Borgida

Heidi Rothenmund

Spring Holter

Kara Semotiuk

Robert Grant

Stephanie Wilson

Malcolm Moore

Steven Narod

Kartik Jhaveri

Masoom A Haider

Steven Gallinger

Affiliations

Soon will be listed here.

Abstract

Background: Pancreatic adenocarcinoma is the fourth leading cause of cancer death.

Methods: A prospective cohort study was undertaken between 2003 and 2011 at a tertiary care centre in Toronto, Canada. Two hundred and sixty-two subjects were enrolled based on an elevated estimated lifetime risk for pancreatic cancer due to known genetic mutations and/or cancer family history. Subjects underwent annual magnetic resonance imaging, followed by additional investigations if abnormal findings were detected. Evidence of malignancy or suspicious macroscopic abnormalities prompted referral for surgical intervention.

Results: Average length of follow-up was 4.2 years, during which 84/262 (32%) subjects demonstrated pancreatic abnormalities. Three participants developed pancreatic adenocarcinoma (one 1.5-cm tumor was resected but recurred, while the other two subjects developed metastatic cancer), and a fourth participant developed a pancreatic neuroendocrine tumor that was resected. Fifteen subjects had radiologic evidence of branch-duct intraductal papillary mucinous neoplasms, of which two underwent surgical resection. Sixty-five subjects had simple pancreatic cysts that have remained stable.

Conclusion: Magnetic resonance imaging can detect small pancreatic tumors and cystic lesions, but further improvement in sensitivity is needed. An understanding of the natural history of pre-invasive lesions in members of high-risk families is necessary for developing a more effective screening program.

Citing Articles

Early detection of pancreatic cancer in the era of precision medicine.

Ahmed T, Kawamoto S, Lopez-Ramirez F, Yasrab M, Hruban R, Fishman E Abdom Radiol (NY). 2024; 49(10):3559-3573.

PMID: 38761272 DOI: 10.1007/s00261-024-04358-w.

Aspects and outcomes of surveillance for individuals at high-risk of pancreatic cancer.

Bogdanski A, van Hooft J, Boekestijn B, Bonsing B, Wasser M, Klatte D Fam Cancer. 2024; 23(3):323-339.

PMID: 38619782 PMC: 11255004. DOI: 10.1007/s10689-024-00368-1.

The role of endoscopic ultrasound in the detection of pancreatic lesions in high-risk individuals.

Overbeek K, Cahen D, Bruno M Fam Cancer. 2024; 23(3):279-293.

PMID: 38573399 PMC: 11255057. DOI: 10.1007/s10689-024-00380-5.

Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations.

Peters M, Eckel A, Seguin C, Davidi B, Howard D, Knudsen A JCO Oncol Pract. 2023; 20(2):278-290.

PMID: 38086003 PMC: 10911581. DOI: 10.1200/OP.23.00495.

Earlier Diagnosis of Pancreatic Cancer: Is It Possible?.

Koltai T Cancers (Basel). 2023; 15(18).

PMID: 37760400 PMC: 10526520. DOI: 10.3390/cancers15184430.

References

Verna E, Hwang C, Stevens P, Rotterdam H, Stavropoulos S, Sy C . Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res. 2010; 16(20):5028-37. DOI: 10.1158/1078-0432.CCR-09-3209. View

Chu D, Kohlmann W, Adler D . Identification and screening of individuals at increased risk for pancreatic cancer with emphasis on known environmental and genetic factors and hereditary syndromes. JOP. 2010; 11(3):203-12. View

Wang W, Chen S, Brune K, Hruban R, Parmigiani G, Klein A . PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol. 2007; 25(11):1417-22. PMC: 2267288. DOI: 10.1200/JCO.2006.09.2452. View

Canto M, Goggins M, Yeo C, Griffin C, Axilbund J, Brune K . Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol. 2004; 2(7):606-21. DOI: 10.1016/s1542-3565(04)00244-7. View

Brune K, Lau B, Palmisano E, Canto M, Goggins M, Hruban R . Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst. 2010; 102(2):119-26. PMC: 2808346. DOI: 10.1093/jnci/djp466. View

Jacobs E, Chanock S, Fuchs C, Lacroix A, McWilliams R, Steplowski E . Family history of cancer and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Int J Cancer. 2010; 127(6):1421-8. PMC: 2926939. DOI: 10.1002/ijc.25148. View

Hruban R, Canto M, Goggins M, Schulick R, Klein A . Update on familial pancreatic cancer. Adv Surg. 2010; 44:293-311. PMC: 2966038. DOI: 10.1016/j.yasu.2010.05.011. View

Poley J, Kluijt I, Gouma D, Harinck F, Wagner A, Aalfs C . The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol. 2009; 104(9):2175-81. DOI: 10.1038/ajg.2009.276. View

Tanno S, Nakano Y, Nishikawa T, Nakamura K, Sasajima J, Minoguchi M . Natural history of branch duct intraductal papillary-mucinous neoplasms of the pancreas without mural nodules: long-term follow-up results. Gut. 2007; 57(3):339-43. DOI: 10.1136/gut.2007.129684. View

10.

de Snoo F, Bishop D, Bergman W, van Leeuwen I, van der Drift C, van Nieuwpoort F . Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res. 2008; 14(21):7151-7. DOI: 10.1158/1078-0432.CCR-08-0403. View

11.

Vasen H, Wasser M, van Mil A, Tollenaar R, Konstantinovski M, Gruis N . Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology. 2010; 140(3):850-6. DOI: 10.1053/j.gastro.2010.11.048. View

12.

. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999; 91(15):1310-6. DOI: 10.1093/jnci/91.15.1310. View

13.

Tanaka M, Kobayashi K, Mizumoto K, Yamaguchi K . Clinical aspects of intraductal papillary mucinous neoplasm of the pancreas. J Gastroenterol. 2005; 40(7):669-75. DOI: 10.1007/s00535-005-1646-4. View

14.

Sipos B, Frank S, Gress T, Hahn S, Kloppel G . Pancreatic intraepithelial neoplasia revisited and updated. Pancreatology. 2008; 9(1-2):45-54. DOI: 10.1159/000178874. View

15.

Langer P, Kann P, Fendrich V, Habbe N, Schneider M, Sina M . Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut. 2009; 58(10):1410-8. DOI: 10.1136/gut.2008.171611. View

16.

Brand R, Lerch M, Rubinstein W, Neoptolemos J, Whitcomb D, Hruban R . Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut. 2007; 56(10):1460-9. PMC: 2000231. DOI: 10.1136/gut.2006.108456. View

17.

Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B . Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010; 467(7319):1114-7. PMC: 3148940. DOI: 10.1038/nature09515. View

18.

Steinberg W, Barkin J, Bradley 3rd E, DiMagno E, Layer P, Canto M . Should patients with a strong family history of pancreatic cancer be screened on a periodic basis for cancer of the pancreas?. Pancreas. 2009; 38(5):e137-50. DOI: 10.1097/MPA.0b013e3181a86b2c. View

19.

Klein A, Brune K, Petersen G, Goggins M, Tersmette A, Offerhaus G . Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004; 64(7):2634-8. DOI: 10.1158/0008-5472.can-03-3823. View

20.

Canto M, Goggins M, Hruban R, Petersen G, Giardiello F, Yeo C . Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol. 2006; 4(6):766-81. DOI: 10.1016/j.cgh.2006.02.005. View